Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T‐cell lymphoma models: Defining molecular mechanisms of resistanceWenlin Shao, Peter Atadja(University of Health and Allied Sciences)International Journal of CancerFebruary 2, 201010.1002/ijc.25218Cited by 90SaveCiteExport RISWatch citationsRelated PapersSETDB1 modulates PRC2 activity at developmental genes independently of H3K9 trimethylation in mouse ES cells|Genome Research|2015|49Abstract CT031: A first-in-human, phase 1a/1b, open-label, dose-escalation and expansion study to investigate the safety, pharmacokinetics, and antitumor activity of the RAF dimer inhibitor BGB-3245 in patients with advanced or refractory tumors|Cancer Research|2023|12